In addition, the cutaneous adverse effects, such as cutaneous squamous cell carcinoma resulted by BRAF-inhibitor–induced paradoxical activation of the MAPK pathway in keratinocytes with upstream activation of signaling by preexisting RAS mutations [6, 7], which can be blocked with the addition of a MEK inhibition. The gene discussed is BRAF; the disease is cutaneous squamous cell carcinoma.